Company Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD).
Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis.
The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure.
Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
| Country | CA |
| IPO Date | Jan 15, 2019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 22 |
| CEO | David G. Elsley MBA |
Contact Details
Address: 2265 Upper Middle Road East Oakville, ON CA | |
| Website | https://www.cardiolrx.com |
Stock Details
| Ticker Symbol | CRDL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001702123 |
| CUSIP Number | 14161Y200 |
| ISIN Number | CA14161Y2006 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David G. Elsley MBA | President, Chief Executive Officer & Director |
| Bernard Lim B.Sc. | Chief Operating Officer |
| Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | Chief Financial Officer, Corporate Secretary & Director |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of Research & Development |
| John A. Geddes BSCPT, MBA | Vice President of Corporate Development |
| Trevor Burns | Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 6-K | Filing |
| Nov 14, 2024 | 6-K | Filing |
| Nov 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 22, 2024 | 6-K | Filing |
| Oct 11, 2024 | 6-K | Filing |
| Oct 10, 2024 | 6-K | Filing |
| Oct 09, 2024 | SUPPL | Filing |
| Oct 09, 2024 | 6-K | Filing |
| Oct 08, 2024 | 6-K | Filing |
| Oct 08, 2024 | SUPPL | Filing |